NASDAQ: CNMD | Healthcare / Medical Devices & Instruments / USA |
97.40 | -3.11 | -3.09% | Vol 287.35K | 1Y Perf -20.44% |
Aug 9th, 2022 16:00 DELAYED |
BID | 96.22 | ASK | 97.84 | ||
Open | 99.98 | Previous Close | 100.51 | ||
Pre-Market | - | After-Market | 97.11 | ||
- - | -0.29 -0.30% |
Target Price | 144.00 | Analyst Rating | Moderate Buy 1.83 | |
Potential % | 47.84 | Finscreener Ranking | ★ 39.98 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | + 37.15 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★ 52.40 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | + 27.07 | |
Price Range Ratio 52W % | 14.14 | Earnings Rating | Sell | |
Market Cap | 2.97B | Earnings Date | 27th Jul 2022 | |
Alpha | 0.00 | Standard Deviation | 0.10 | |
Beta | 1.56 |
Today's Price Range 96.84100.99 | 52W Range 87.24159.11 | 5 Year PE Ratio Range 25.30530.40 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Neutral |
Performance | |||
---|---|---|---|
1 Week | 2.08% | ||
1 Month | 5.36% | ||
3 Months | -7.44% | ||
6 Months | -29.07% | ||
1 Year | -20.44% | ||
3 Years | 6.05% | ||
5 Years | 102.52% | ||
10 Years | 296.40% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 3.01 | |||
ROE last 12 Months | 9.18 | |||
ROA (5Y Avg) | 1.14 | |||
ROA last 12 Months | 3.94 | |||
ROC (5Y Avg) | 4.25 | |||
ROC last 12 Months | 6.24 | |||
Return on invested Capital Q | 1.29 | |||
Return on invested Capital Y | 2.09 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 4.50 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
45.80 | ||||
3.59 | ||||
3.68 | ||||
35.50 | ||||
111.30 | ||||
2.71 | ||||
-9.73 | ||||
26.74 | ||||
3.53B | ||||
Forward PE | 24.19 | |||
PEG | 3.72 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.10 | ||||
2.60 | ||||
0.47 | ||||
0.91 | ||||
3.70 | ||||
Leverage Ratio | 2.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
56.40 | ||||
10.90 | ||||
17.70 | ||||
4.80 | ||||
7.04 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
765.13M | ||||
25.91 | ||||
3.46 | ||||
4.94 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.84 | ||||
0.80 | ||||
0.00 | ||||
0.00 | ||||
Payout ratio | 44.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | 0.76 | 0.76 | 0.00 |
Q01 2022 | 0.62 | 0.70 | 12.90 |
Q04 2021 | 1.05 | 1.07 | 1.90 |
Q03 2021 | 0.77 | 0.80 | 3.90 |
Q02 2021 | 0.62 | 0.71 | 14.52 |
Q01 2021 | 0.43 | 0.63 | 46.51 |
Q04 2020 | 0.78 | 0.84 | 7.69 |
Q03 2020 | 0.25 | 0.88 | 252.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 0.76 | -15.56 | Negative |
9/2022 QR | 0.94 | 0.00 | - |
12/2022 FY | 3.51 | -5.14 | Negative |
12/2023 FY | 4.01 | -6.09 | Negative |
Next Report Date | - |
Estimated EPS Next Report | 0.76 |
Estimates Count | 6 |
EPS Growth Next 5 Years % | 12.30 |
Volume Overview | |
---|---|
Volume | 287.35K |
Shares Outstanding | 30.47K |
Shares Float | 21.42M |
Trades Count | 6.24K |
Dollar Volume | 28.23M |
Avg. Volume | 406.95K |
Avg. Weekly Volume | 372.07K |
Avg. Monthly Volume | 364.42K |
Avg. Quarterly Volume | 484.37K |
Conmed Corp. - Ordinary Shares (NASDAQ: CNMD) stock closed at 100.51 per share at the end of the most recent trading day (a 3.61% change compared to the prior day closing price) with a volume of 273.98K shares and market capitalization of 2.97B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 3400 people. Conmed Corp. - Ordinary Shares CEO is Curt R. Hartman.
The one-year performance of Conmed Corp. - Ordinary Shares stock is -20.44%, while year-to-date (YTD) performance is -29.1%. CNMD stock has a five-year performance of 102.52%. Its 52-week range is between 87.24 and 159.11, which gives CNMD stock a 52-week price range ratio of 14.14%
Conmed Corp. - Ordinary Shares currently has a PE ratio of 45.80, a price-to-book (PB) ratio of 3.59, a price-to-sale (PS) ratio of 3.68, a price to cashflow ratio of 35.50, a PEG ratio of 2.32, a ROA of 3.94%, a ROC of 6.24% and a ROE of 9.18%. The company’s profit margin is 7.04%, its EBITDA margin is 17.70%, and its revenue ttm is $765.12 Million , which makes it $25.91 revenue per share.
Of the last four earnings reports from Conmed Corp. - Ordinary Shares, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.76 for the next earnings report. Conmed Corp. - Ordinary Shares’s next earnings report date is -.
The consensus rating of Wall Street analysts for Conmed Corp. - Ordinary Shares is Moderate Buy (1.83), with a target price of $144, which is +47.84% compared to the current price. The earnings rating for Conmed Corp. - Ordinary Shares stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Conmed Corp. - Ordinary Shares has a dividend yield of 0.84% with a dividend per share of $0.80 and a payout ratio of 44.00%.
Conmed Corp. - Ordinary Shares has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.11, ATR14 : 3.41, CCI20 : 32.35, Chaikin Money Flow : 0.16, MACD : -0.12, Money Flow Index : 50.97, ROC : -1.61, RSI : 52.16, STOCH (14,3) : 54.60, STOCH RSI : 0.74, UO : 49.45, Williams %R : -45.40), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Conmed Corp. - Ordinary Shares in the last 12-months were: Barbara J Schwarzentraub (Option Excercise at a value of $0), Brent Lalomia (Option Excercise at a value of $0), Brian P. Concannon (Option Excercise at a value of $518 729), Brian P. Concannon (Sold 12 984 shares of value $1 762 324 ), Charles M. Farkas (Option Excercise at a value of $0), Curt R. Hartman (Sold 0 shares of value $-3 976 205 ), Curt R. Hartman (Sold 5 000 shares of value $664 540 ), Daniel S. Jonas (Sold 0 shares of value $-2 874 836 ), Daniel S. Jonas (Sold 33 957 shares of value $4 850 850 ), David M. Bronson (Option Excercise at a value of $0), Jaclyn Peterson (Option Excercise at a value of $0), Jerome J Lande (Option Excercise at a value of $0), Jerome J Lande (Sold 7 521 shares of value $870 493 ), John E. Kennedy (Option Excercise at a value of $1 830 003), John E. Kennedy (Sold 32 272 shares of value $4 602 438 ), John L. Workman (Option Excercise at a value of $0), Johonna Pelletier (Sold 0 shares of value $-674 414 ), Johonna Pelletier (Sold 9 197 shares of value $1 421 102 ), LaVerne Council (Option Excercise at a value of $0), Mark E. Tryniski (Option Excercise at a value of $855 506), Mark E. Tryniski (Sold 12 420 shares of value $1 943 745 ), Martha Goldberg Aronson (Option Excercise at a value of $0), Patrick J. Beyer (Option Excercise at a value of $4 805 721), Patrick J. Beyer (Sold 42 729 shares of value $6 270 747 ), Stanley W. Peters (Sold 0 shares of value $-1 001 269 ), Stanley W. Peters (Sold 24 700 shares of value $3 744 890 ), Todd W. Garner (Option Excercise at a value of $425 124), Todd W. Garner (Sold 13 734 shares of value $1 693 093 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgery. The firm currently reports through two reporting units, orthopedic surgery (52% of 2018 sales) and general surgery (48%). From a geographic perspective the firm is U.S. centric, with domestic sales accounting for 52% of revenue, EMEA accounting for 19%, APAC at 17%, and the non-U.S. Americas region driving the remaining 12%.
CEO: Curt R. Hartman
Telephone: +1 727 392-6464
Address: 11311 Concept Boulevard, Largo 33773, FL, US
Number of employees: 3 400
Fri, 21 Jan 2022 12:25 GMT Analysts Offer Insights on Healthcare Companies: Conmed (CNMD) and Edwards Lifesciences (EW)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.